The influence of LRRK2 mutations on cholinergic system in manifest and prodromal stage of Parkinson’s disease: a positron emission tomography study
Objective: To evaluate the effects of leucine-rich repeat kinase 2 (LRRK2) mutations on the central cholinergic system in both manifesting and non-manifesting carriers using PET…Evaluation of the [ 99mTc] – TRODAT- 1 SPECT in the diagnosis of Parkinson’s disease and other movement disorders
Objective: Evaluation of the [ 99mTc] - TRODAT- 1 SPECT in the diagnosis of PD and other MD. Create a DATA bank for our population.…PET examination of the monoamine transporter with 11C-beta-CIT
Objective: To investigate the utility of 11C-β-CIT PET scan on Parkinson's disease diagnosis. Background: The monoamine reuptake sites transport dopamine, noradrenaline and serotonin from the…A heterozygous splicing variant in NPC2 in a patient with PSP
Objective: Clinical, neuroimaging, genetic and biochemical characterization of a patient with a PSP-like phenotype carrying a splicing mutation in NPC2. Background: Niemann-Pick type C disease…Density of metabotropic glutamate receptors subtype 1 in de novo patients with Parkinson’s disease using 11C-ITMM PET
Objective: To investigate the mapping of metabotropic glutamate receptor subtype 1 (mGluR1) in elderly normal and de novo patients with Parkinson's disease (PD) using N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-4-11C…Multimodal imaging assessment of nigrostriatal pathway in Parkinson’s disease using 11C-PE2I PET and neuromelanin-sensitive MR
Objective: To evaluate the nigrostratal pathway with multimodal assessment using striatal 11C-PE2I PET and nigral Neuromelanin-sensitive MR in Parkinson's disease. Background: The main pathological features…Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [18F]MNI-659 PET imaging
Objective: To evaluate the feasibility of [18F]MNI-659 PET, a striatal PDE10A imaging tracer, as a imaging biomarker in PD. Background: PDE10 is highly and specifically…Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease
Objective: The aims of this study were to quantify striatal uptake of 18F-DOPA and 11C-PE2I in the same group of PD patients, to assess the…Persistent drug-induced parkinsonism with normal dopamine transporter imaging
Objective: We investigated whether patients with persistent drug-induced parkinsonism (DIP) showing visually normal dopamine transporter (DAT) imaging had minimal changes in striatal DAT activity using…Cerebellar GABA-A receptor activity is inversely correlated with gait speed in Parkinson’s disease
Objective: To investigate the relationship between regional cerebral expression of benzodiazepine receptors and gait speed in Parkinson's disease (PD). Background: Flumazenil is a short-acting intravenously…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- Next Page »